|
Europe Lymphoma Articles
Europe Lymphoma News : A 'family affair' to counter human trafficking Tue, 07 Sep 2010 18:31:59 GMT The National Oceanic and Atmospheric Administration (NOAA), the U.S. Environmental Protection Agency (EPA) and the Office of Science and Technology Policy (OSTP) released a report today that showed dissolved oxygen levels have dropped by about 20 percent from their long-term average in the Gulf of Mexico in areas where federal and independent scientists previously reported the presence of ...Europe Lymphoma News : Ripples in the cosmic background Tue, 07 Sep 2010 18:02:49 GMT (PhysOrg.com) -- The universe was created 13.73 billion years ago in a blaze of light -- the big bang. We also think that, about 380,000 years later, after matter (mostly hydrogen atoms) had cooled enough for neutral atoms to form, light was able to travel through space relatively freely. We see that light today as the cosmic microwave background radiation (CMBR). The light appears extremely ...Research and Markets: Epigenetics Therapeutics to 2017 - High Market Potential for Epigenetics Drugs in Acute Myeloid ... Mon, 06 Sep 2010 14:21:00 GMT DUBLIN----Research and Markets has announced the addition of the "Epigenetics Therapeutics to 2017 - High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma" report to their offering.Research and Markets: Epigenetics Therapeutics to 2017 - High Market Potential for Epigenetics Drugs in Acute Myeloid ... Mon, 06 Sep 2010 14:30:37 GMT DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/f7e7a7/epigenetics_therap) has announced the addition of the "Epigenetics Therapeutics to 2017 - High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma" report to their offering. Epigenetics Therapeutics to 2017 - High ...Reportlinker Adds Biomarkers - technologies, markets and companies Tue, 07 Sep 2010 14:39:00 GMT Reportlinker.com announces that a new market research report is available in its catalogue:Celgene Officially Notified Of ANDA Filing For REVLIMID(R) Mon, 06 Sep 2010 14:41:35 GMT Celgene Corporation (NASDAQ: CELG) announced it has received a Paragraph IV Certification Letter advising that Natco Pharma Limited of Hyderabad, India, submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA). The application requests authorization to manufacture and market generic versions of REVLIMID® (lenalidomide) 5, 10, 15 and 25 mg capsules in ...GBI Research's report analyzes licensing agreement to shape global market Fri, 03 Sep 2010 10:28:01 GMT ReportsandReports announces it will carry the Epigenetics Therapeutics to 2017 - High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma Market Research Report in its store.International study to improve treatments for Duchenne muscular dystrophy launched Fri, 03 Sep 2010 12:27:22 GMT A large international study aimed at improving the care of muscular dystrophy patients worldwide is being launched by physicians, physical therapists, and researchers at the University of Rochester Medical Center.Therapeutic Workshops To Highlight Opportunities In Biotech At 9th Annual BIO Investor Forum Thu, 02 Sep 2010 16:12:58 GMT BIO today announced the preliminary set of speakers who will be featured on the Therapeutic Workshops during the 9th Annual BIO Investor Forum - a national meeting focused on investment trends and opportunities in the life-sciences with a focus on public and venture-stage growth companies. Hosted by the Biotechnology Industry Organization (BIO), the 9th annual event will take place at the Palace ...ThromboGenics second microplasmin Phase III trial for non-surgical treatment of VMA meets primary endpoint Thu, 02 Sep 2010 10:12:42 GMT ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer announces that its second Phase III trial evaluating microplasmin for the non-surgical treatment of vitreomacular adhesion (VMA) has met its primary endpoint.Therapeutic Workshops to Highlight Opportunities in Biotech at 9th Annual BIO Investor Forum Wed, 01 Sep 2010 19:44:48 GMT WASHINGTON--(BUSINESS WIRE)--BIO today announced the preliminary set of speakers who will be featured on the Therapeutic Workshops during the 9th Annual BIO Investor Forum – a national meeting focused on investment trends and opportunities in the life-sciences with a focus on public and venture-stage growth companies. Hosted by the Biotechnology Industry Organization (BIO), the 9th annual event ...Therapeutic Workshops to Highlight Opportunities in Biotech at 9th Annual BIO Investor Forum Wed, 01 Sep 2010 19:25:12 GMT WASHINGTON, D.C. (Wednesday, September 1, 2010) BIO today announced the preliminary set of speakers who will be featured on the Therapeutic Workshops during the 9th Annual BIO Investor Forum – a national meeting focused on investment trends and opportunities in the life-sciences with a focus on public and venture-stage growth companies. Hosted by the Biotechnology Industry Organization (BIO ...Therapeutic Workshops to Highlight Opportunities in Biotech at 9th Annual BIO Investor Forum Wed, 01 Sep 2010 19:35:00 GMT WASHINGTON----BIO today announced the preliminary set of speakers who will be featured on the Therapeutic Workshops during the 9th Annual BIO Investor Forum – a national meeting focused on investment trends and opportunities in the life-sciences with a focus on public and venture-stage growth companies. |
Infectious and parasitic diseases |
|
|
< Home > |
||